# Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

> **NCT06180057** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 24 (actual)

## Conditions studied

- Cerebrotendinous Xanthomatoses

## Interventions

- **DRUG:** Chenodeoxycholic acid
- **DRUG:** Chenodeoxycholic acid leadiant

## Key facts

- **NCT ID:** NCT06180057
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-12
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-08-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180057, "Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06180057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*